Treatment of experimental visceral leishmaniasis with lymphokine encapsulated in liposomes.
Highly susceptible mice were infected with Leishmania donovani chagasi and were treated with supernatants, free or encapsulated in liposomes, from concanavalin A-stimulated or unstimulated mouse spleen cell cultures. Treatment consisted of multiple i.v. injections beginning 2 days before to 2 days after infection. Mice treated with lymphokine-rich supernatants encapsulated in liposomes had significantly fewer liver parasites than the control groups, demonstrating in vivo activity of lymphokine against an infectious organism.
D000818:Animals; D003208:Concanavalin A / Q000627:therapeutic use; D007167:Immunotherapy; D007891:Leishmania / Q000254:growth & development / Q000276:immunology; D007898:Leishmaniasis, Visceral / Q000276:immunology / Q000469:parasitology / Q000628:therapy*; D008081:Liposomes / Q000008:administration & dosage*; D008109:Liver Diseases, Parasitic / Q000628:therapy; D008222:Lymphokines / Q000627:therapeutic use*; D008264:Macrophages / Q000276:immunology / Q000469:parasitology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D013154:Spleen / Q000276:immunology
D008081:Liposomes; D008222:Lymphokines; C021649:concanavalin A-induced helper factors; D003208:Concanavalin A